CASGEVY: Revolutionizing Gene Therapy for Blood Disorders
CASGEVY , developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is the world's first CRISPR-based gene-editing therapy approved for sickle cell disease and transfusion-dependent beta-thalassemia. Its historic approval marks a turning point in medicine, offering patients a potential one-time functional cure rather than lifelong disease management. What Is CASGEVY and How Does It Work? CASGEVY (exagamglogene autotemcel) works by editing a patient's own stem cells to reactivate fetal hemoglobin production, compensating for the defective adult hemoglobin responsible for these debilitating conditions. The therapy delivers a durable response, with clinical trials showing that the overwhelming majority of treated patients became free from severe crises. CASGEVY Pricing and Cost Analysis One of the most discussed aspects of this therapy is its price point. A deep CASGEVY Cost Analysis reveals a list price of approximately $2.2 million per treatment in the United States. While...